Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology

Galmed Pharmaceuticals ( (GLMD) ) has issued an update.

On May 22, 2025, Galmed Pharmaceuticals announced its financial results for the first quarter of 2025, showing a net loss of $1.1 million, an improvement from the $1.3 million loss in the same period last year. The company highlighted significant developments, including the enhancement of Bayer’s Regorafenib effect in GI cancer models through Aramchol and a new semaglutide sublingual formulation. These advancements, along with a $6.5 million capital raise, position Galmed to strengthen its market presence and support its ongoing research and development initiatives.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for cardiometabolic diseases and gastrointestinal oncological indications. The company is primarily known for its work on Aramchol, a compound aimed at treating liver diseases, and is expanding its pipeline to include innovative products targeting cardiometabolic conditions.

Average Trading Volume: 2,422,097

Technical Sentiment Signal: Sell

Current Market Cap: $3.09M

For detailed information about GLMD stock, go to TipRanks’ Stock Analysis page.